CFTR and cystic fibrosis: Garbuzenko et al. in 2019 found that delivering these two hydrophobic drugs within a nebulized NLC formulation restored the activity of CFTR and reduced the volume of fibrotic tissue present in the treated mouse lungs, thereby treating CF effectively in the murine model [79].